Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Fuji
Baxter
Queensland Health
Johnson and Johnson
Chinese Patent Office
Express Scripts
Healthtrust
AstraZeneca
Fish and Richardson

Generated: October 21, 2017

DrugPatentWatch Database Preview

Alvogen Company Profile

« Back to Dashboard

What is the competitive landscape for ALVOGEN, and what generic alternatives to ALVOGEN drugs are available?

ALVOGEN has forty-three approved drugs.

There is one US patent protecting ALVOGEN drugs.

There is one patent family member on ALVOGEN drugs in one country and eighty-one supplementary protection certificates in twelve countries.

Summary for Applicant: Alvogen

International Patents:1
US Patents:1
Tradenames:36
Ingredients:33
NDAs:43
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Alvogen
DAPSONE
dapsone
TABLET;ORAL205429-002Jan 7, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
Alvogen Malta
NAPRELAN
naproxen sodium
TABLET, EXTENDED RELEASE;ORAL020353-002Jan 5, 1996ABRXYesNo► Subscribe► Subscribe► Subscribe
Alvogen
DAPSONE
dapsone
TABLET;ORAL205429-001Jan 7, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
Alvogen Malta
CARBIDOPA
carbidopa
TABLET;ORAL204291-001Jan 8, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
Alvogen Malta
ZESTRIL
lisinopril
TABLET;ORAL019777-004May 19, 1988ABRXYesYes► Subscribe► Subscribe► Subscribe
Alvogen Malta
ATENOLOL
atenolol
TABLET;ORAL072303-001Jul 15, 1988ABRXNoNo► Subscribe► Subscribe► Subscribe
Alvogen Inc
ACETYLCYSTEINE
acetylcysteine
SOLUTION;INHALATION, ORAL203853-001Jun 21, 2012ANRXNoNo► Subscribe► Subscribe► Subscribe
Alvogen Malta
TENORMIN
atenolol
TABLET;ORAL018240-004Apr 9, 1990ABRXYesNo► Subscribe► Subscribe► Subscribe
Alvogen Malta
ZESTORETIC
hydrochlorothiazide; lisinopril
TABLET;ORAL019888-003Nov 18, 1993ABRXYesNo► Subscribe► Subscribe► Subscribe
Alvogen Malta
BUDESONIDE
budesonide
CAPSULE;ORAL206724-001Nov 23, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Alvogen

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Alvogen Malta
ZESTRIL
lisinopril
TABLET;ORAL019777-005Apr 29, 1993► Subscribe► Subscribe
Alvogen
ADALAT CC
nifedipine
TABLET, EXTENDED RELEASE;ORAL020198-003Apr 21, 1993► Subscribe► Subscribe
Alvogen Malta
ZESTRIL
lisinopril
TABLET;ORAL019777-003May 19, 1988► Subscribe► Subscribe
Alvogen Malta
NAPRELAN
naproxen sodium
TABLET, EXTENDED RELEASE;ORAL020353-001Jan 5, 1996► Subscribe► Subscribe
Alvogen Malta
SPECTAZOLE
econazole nitrate
CREAM;TOPICAL018751-001Dec 23, 1982► Subscribe► Subscribe
Alvogen Malta
TENORMIN
atenolol
TABLET;ORAL018240-002Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Alvogen Malta
NAPRELAN
naproxen sodium
TABLET, EXTENDED RELEASE;ORAL020353-003Jan 5, 1996► Subscribe► Subscribe
Alvogen
ADALAT CC
nifedipine
TABLET, EXTENDED RELEASE;ORAL020198-001Apr 21, 1993► Subscribe► Subscribe
Alvogen Malta
ZESTORETIC
hydrochlorothiazide; lisinopril
TABLET;ORAL019888-002Jul 20, 1989► Subscribe► Subscribe
Alvogen Malta
TENORMIN
atenolol
TABLET;ORAL018240-004Apr 9, 1990► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for ALVOGEN drugs

Drugname Dosage Strength Tradename Submissiondate
bupropion hydrochloride
Extended-release Tablets450 mg
FORFIVO XL
2/28/2013

Non-Orange Book Patents for Alvogen

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,703,191Controlled-release pharmaceutical tablets► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Alvogen Drugs

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)2008038155► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Alvogen Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB02/033United Kingdom► SubscribePRODUCT NAME: FORMOTEROL (OPTIONALLY IN THE FORM OF THE FREE BASE OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF, OR A SOLVATE OF SUCH FREE BASE OR SALT ESPECIALLY AS FORMOTEROL FUMARATE DIHYDRATE) AND BUDESONIDE; REGISTERED: SE SE16047, 16048 20000825; UK PL17901/0091 20010515; UK PL17901/0092 20010515
2013025,C1304992Lithuania► SubscribePRODUCT NAME: CLINDAMYCINUM + TRETINOINUM; REGISTRATION NO/DATE: LT/1/13/3279/001, 2013 04 26 LT/1/13/3279/002, 2013 04 26 PA1332/043/001 20130323
90020-1Sweden► SubscribePRODUCT NAME: SACUBITRIL AND VALSARTAN, AS SACUBITRIL VALSARTAN SODIUM SALT COMPLEX, I.E. TRISODIUM 3-((1S,3R)-1-BIPHENYL-4-YLMETHYL-3- ETHOXYCARBONYL-1-BUTYLCARBAMOYL)PROPIONATE-(S)-3-METHYL-2- (PENTANOYL2-(TETRAZOL-5-YLATE)BIPHENYL-4- YLMETHYLAMINO)BUTYRATE HEMIPENTAHYDRATE; REG. NO/DATE: EU/1/15/1058 20151123
C/GB01/045United Kingdom► SubscribePRODUCT NAME: NATEGLINIDE OR SALTS THEREOF; REGISTERED: CH 55401 20000928; CH 55402 20000928; UK EU/1/01/174/001 20010403; UK EU/1/01/174/002 20010403; UK EU/1/01/174/003 20010403; UK EU/1/01/174/004 20010403; UK EU/1/01/174/005 20010403; UK EU/1/01/174/006 20010403; UK EU/1/01/174/019 20010403; UK EU/1/01/174/020 20010403; UK EU/1/01/174/021 20010403; UK EU/1/01/174/013 20010403; UK EU/1/01/174/014 20010403; UK EU/1/01/174/015 20010403; UK EU/1/01/174/016 20010403; UK EU/1/01/174/017 20010403; UK EU/1/01/174/018 20010403; UK EU/1/01/174/007 20010403; UK EU/1/01/174/008 20010403; UK EU/1/01/174/009 20010403; UK EU/1/01/174/010 20010403; UK EU/1/01/174/011 20010403; UK EU/1/01/174/012 2001040
C0044France► SubscribePRODUCT NAME: NATEGLINIDE; NAT. REGISTRATION NO/DATE: EU/1/01/174/001 20010403; FIRST REGISTRATION: LI - 55401 20000928
C0022France► SubscribePRODUCT NAME: MONTELUKAST SODIUM; REGISTRATION NO/DATE IN FRANCE: NL 23 133 DU 19980320; REGISTRATION NO/DATE AT EEC: 13 651 DU 19970825
2011 00026Denmark► SubscribePRODUCT NAME: A COMBINATION OF OLMESARTAN MEDOXOMIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE; NAT. REG. NO/DATE: 46260-46269 (DK) 20110323; FIRST REG. NO/DATE: DE 79810.00.00 20101216
2011005Lithuania► SubscribePRODUCT NAME: NAPROXENUM + ESOMEPRAZOLUM; REGISTRATION NO/DATE: LT/1/10/2302/001-LT/1/10/2302/012 20110126
C/GB96/053United Kingdom► SubscribePRODUCT NAME: DOXORUBICIN SULPHATE; REGISTERED: UK EU/1/96/011/001 19960621; UK EU/1/96/011/002 19960621
90018-6Sweden► SubscribePRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REG. NO/DATE: EU/1/14/983 20150119
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Citi
Cantor Fitzgerald
Johnson and Johnson
Accenture
Merck
Deloitte
AstraZeneca
Queensland Health
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot